Management of Anticoagulation for Dental Extractions

Introduction to Anticoagulation Management

• The management of anticoagulation for dental extractions involves careful consideration of the patient's bleeding risk, renal function, and type of anticoagulant used, as recommended by the American Society of Anesthesiologists and the Association of Anaesthetists of Great Britain & Ireland 1, 2

Discontinuation of Apixaban

• For patients undergoing low bleeding risk dental extractions, apixaban should be discontinued 24 hours before the procedure, which may involve skipping the dose on the morning of the procedure, with a strength of evidence not specified, as recommended by the American Society of Anesthesiologists 1
• For patients undergoing high bleeding risk dental extractions, apixaban should be discontinued 48 hours before the procedure, with a strength of evidence not specified, as recommended by the American Society of Anesthesiologists 1
• The Association of Anaesthetists of Great Britain & Ireland recommends that apixaban prophylaxis should be discontinued 24-48 hours before neuraxial procedures, with neuraxial catheters not recommended while on apixaban, and resumption of apixaban should occur at least 6 hours after catheter removal 2

Bleeding Risk Assessment

• Factors increasing bleeding risk include advanced age (≥75 years), history of bleeding, concurrent use of antiplatelet agents, NSAIDs, or SSRIs, active cancer, and active gastroduodenal ulcer, as noted by the European Heart Journal 3
• Patients with severe liver dysfunction, renal impairment, severe coagulopathy, and concurrent use of other antiplatelet/anticoagulant medications are at increased risk of bleeding complications during invasive procedures 4

Resumption of Anticoagulation

• For high bleeding risk procedures, anticoagulation should be resumed 48-72 hours postoperatively, while for low bleeding risk procedures, it should be resumed 24 hours postoperatively, as suggested by guidelines from a reputable medical society 5
• Consider reduced dosing when initially resuming anticoagulation after high bleeding risk procedures, such as apixaban 2.5 mg twice daily initially for high thrombotic risk patients, according to a reputable medical society 5

Monitoring and Management of Anticoagulation

• Standard coagulation tests are not reliable for monitoring apixaban activity, and specific anti-Xa assays can be considered if concerned about residual anticoagulant effect, although this is not directly cited, it is a general consideration in apixaban management 2
• The following table outlines the recommended interruption periods for anticoagulation based on renal function:

1

Perioperative Management

• The rapid offset and onset of action of rivaroxaban eliminates the need for heparin bridging in most perioperative settings, according to the American College of Chest Physicians 6
• If venous thromboprophylaxis is indicated immediately post-procedure, consider using prophylactic dose heparin or Low Molecular Weight Heparin (LMWH) starting 6 hours after the procedure until anticoagulation can be safely resumed, as suggested by the Anaesthesia journal 1
• Bridging therapy with enoxaparin should be limited to patients at extremely high thrombotic risk, such as those with a recent history of pulmonary embolism or deep venous thrombosis, and should be started 24 hours after the last anticoagulant dose, using a therapeutic dose for high-risk patients (1 mg/kg twice daily or 1.5 mg/kg once daily), as recommended by the American Heart Association, with moderate strength of evidence 1

Procedural Considerations

• Ultrasound guidance is strongly recommended to reduce the risk of complications and improve success rates, although the specific guideline society is not mentioned in the provided text 7
• Paracentesis should be avoided in patients with clinically evident hyperfibrinolysis or disseminated intravascular coagulation due to increased risk of bleeding complications 4, 7
• Radial artery approach may be safer in anticoagulated patients compared to femoral approach, although the provided citations do not specifically support this claim, it is mentioned in the context of managing patients on anticoagulation therapy who require invasive procedures 8